Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss. For weight management, the same molecule is available as Wegovy, which is FDA-approved for chronic weight management. At PEAK, we prescribe Wegovy for weight-loss patients.
The Bottom Line
Ozempic (semaglutide) should be stopped at least 2 months before attempting to conceive. It is not recommended during pregnancy or breastfeeding. This applies to both Ozempic and Wegovy, as they contain the same active ingredient.
Why Semaglutide Is Not Recommended in Pregnancy
Animal studies have shown that semaglutide causes embryo-fetal toxicity at doses lower than the maximum human dose. While animal data doesn’t always translate directly to humans, the findings are concerning enough that the prescribing information carries a clear warning:
- In animal reproduction studies, semaglutide caused embryo lethality and structural abnormalities at clinically relevant doses
- Reduced fetal growth and skeletal variations were observed in multiple animal species
- The mechanism may relate to reduced maternal nutrition (from appetite suppression) and/or direct effects on fetal development
There are no adequate human studies of semaglutide in pregnancy. The lack of human data combined with concerning animal findings means the medication carries a pregnancy risk summary recommending discontinuation before conception.
Accidental Exposure
If you discover you’re pregnant while taking Ozempic:
- Stop the medication immediately and contact your provider
- Don’t panic—early exposure doesn’t automatically mean harm. The risk increases with continued exposure
- Your provider will discuss monitoring options and prenatal care adjustments
- Report the exposure to the Novo Nordisk pregnancy registry if one is available
The 2-Month Washout Period
Novo Nordisk recommends stopping semaglutide at least 2 months before planned conception. This recommendation is based on the medication’s pharmacokinetics:
- Semaglutide has a half-life of approximately 1 week
- After stopping, it takes roughly 5–7 half-lives for the medication to be essentially eliminated
- That translates to approximately 5–7 weeks for near-complete clearance
- The 2-month recommendation provides a safety margin beyond the minimum clearance time
The 2-month washout period is a minimum, not a target. If you're planning pregnancy, discuss timing with your provider well in advance—ideally 3–6 months before you want to start trying.
Semaglutide and Fertility
While semaglutide itself doesn’t enhance fertility, the weight loss it produces can have significant positive effects on reproductive health:
- Improved ovulation: Weight loss of 5–10% can restore regular ovulatory cycles in women with obesity-related anovulation
- PCOS improvement: Weight loss improves insulin resistance and hormonal balance in women with polycystic ovary syndrome, often restoring fertility
- Better IVF outcomes: Lower BMI is associated with improved success rates in assisted reproductive technology
- Reduced pregnancy complications: Starting pregnancy at a lower weight reduces risks of gestational diabetes, preeclampsia, and complications during delivery
Unintended pregnancy risk: Because weight loss can improve fertility even before your cycle seems regular, women of reproductive age on semaglutide should use reliable contraception throughout treatment and during the 2-month washout period.
The “Ozempic Baby” Phenomenon
Media reports of unexpected pregnancies on GLP-1 medications have highlighted an important clinical reality: weight loss—even modest amounts—can restore fertility in women who believed they couldn’t conceive. This underscores the need for contraception counseling when prescribing semaglutide to women of reproductive age.
Additionally, semaglutide may reduce the effectiveness of oral contraceptives by slowing gastric absorption. Your provider may recommend non-oral contraception methods (IUD, implant, injection) during treatment.
Planning for Pregnancy While on Semaglutide
If you’re considering pregnancy while on Ozempic or Wegovy, the ideal approach involves:
- Discuss timing with your provider 3–6 months before your target conception date
- Maximize weight loss and metabolic health while on medication, knowing that you’re building a healthier foundation for pregnancy
- Stop semaglutide at least 2 months before trying to conceive
- Transition to pregnancy-safe weight management strategies: nutrition counseling, exercise, and behavioral support
- Use reliable contraception until you’ve completed the washout period and are ready to conceive
- Expect some weight regain after stopping—this is normal and should be managed with lifestyle strategies, not medication
Semaglutide and Breastfeeding
The safety of semaglutide during breastfeeding is unknown:
- It is not known whether semaglutide passes into human breast milk
- In animal studies, semaglutide was detected in the milk of lactating rats
- The appetite-suppressing effects could theoretically affect milk production or quality
- The prescribing information recommends considering the benefits of breastfeeding and the mother’s need for medication
Most providers recommend waiting until breastfeeding is complete before restarting semaglutide. Discuss the timing with your provider based on your individual circumstances.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
